Jay Shankar, MD
Nephrology · Victorville, CANPI 1164431318
Payments from drug & device makers
Across 253 payments — averaging $6020.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$809K
- AstraZeneca$187K
- Astrazeneca UK Limited$168K
- Eli Lilly$110K
- Bayer$109K
- Merck$43K
- plus $98K from 24 others
Across 1 payment — averaging $12,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$12K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 59 | $809,447 |
| AstraZeneca | 26 | $186,803 |
| Astrazeneca UK Limited | 7 | $167,833 |
| Eli Lilly | 3 | $109,673 |
| Bayer | 19 | $108,585 |
| Merck | 3 | $43,285 |
| Boehringer Ingelheim International GmbH | 19 | $28,356 |
| OPKO Pharmaceuticals, LLC | 10 | $19,270 |
| Amgen(2 entities) | 14 | $14,774 |
| Pfizer | 3 | $14,462 |
| Travere Therapeutics, Inc. | 7 | $9,498 |
| Masimo Corporation | 6 | $8,125 |
| Outset Medical Inc | 1 | $994 |
| Akebia Therapeutics Inc | 17 | $388 |
| Otsuka America Pharmaceutical, Inc. | 11 | $337 |
| Vifor Pharma, Inc. | 10 | $267 |
| Welch Allyn | 2 | $206 |
| Calliditas Therapeutics US Inc. | 6 | $150 |
| GSK | 5 | $130 |
| Ardelyx, Inc. | 7 | $130 |
| Baxter Healthcare | 1 | $121 |
| Fresenius USA Marketing, Inc. | 8 | $119 |
| Boehringer Ingelheim | 2 | $39 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Nxstage Medical, Inc. | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Novartis | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Medtronic | 1 | $14 |
How this compares
$1,523,155 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Victorville
- Edgard Vera TapiaVictorville$1.7M
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.